Should I Buy SKIN? SKIN 2026 Analysis

Should You Buy Beauty Health Co (SKIN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.500

1 Day change

-0.66%

52 Week Range

2.690

Analysis Updated At

2026/01/30

Not a good buy right now for an impatient investor. SKIN is trading with weakening momentum (bearish MACD expansion) and no proprietary buy signals, while fundamentals in the latest quarter show shrinking revenue and deeper losses. With price sitting near key support (~1.46) and only modest upside indications, the risk/reward does not justify an immediate entry; best stance is hold/avoid new buys until momentum improves.

Technical Analysis

Price/Trend: Current price 1.495 (-1.32%) in a slightly down tape (SPX -0.23%). Momentum is soft. Indicators: MACD histogram is negative (-0.00327) and negatively expanding (bearish). RSI(6)=41.7 is neutral-to-weak (not oversold). Moving averages: Converging MAs suggests consolidation rather than a confirmed uptrend. Levels: Pivot 1.511 is overhead; resistance at 1.564 then 1.597. Support at 1.457 then 1.424. At 1.495, the stock is closer to support than resistance, but lacks a confirmed reversal signal. Pattern-based odds: Similar-pattern model suggests a 70% chance of modest gains (+2.16% next day, +2.57% next week, +8.02% next month), but these are not supported by current MACD momentum yet—more consistent with a potential bounce than a durable trend change.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: Open interest put/call of 0.34 is call-heavy (bullish skew). Put volume is effectively zero today, but total option volume is also tiny (5 contracts), so the read-through is weak. Volatility: 30D IV ~97.5% vs HV ~75.2% (options pricing elevated). IV percentile 24 and IV rank 12 indicate IV is not high versus its own recent history—less urgency/panic priced in. Positioning note: Today’s open interest (9,995) is high vs its average (today vs avg ~128.6), suggesting positioning exists, but today’s trading volume is muted—more “standing positioning” than active new risk-taking.

Technical Summary

Sell

Buy

Positive Catalysts

leans constructive.
where short-term bounces can occur if selling pressure fades.

Neutral/Negative Catalysts

Bearish momentum: MACD negative and expanding indicates downside pressure isn’t finished.

Financial Performance

Latest quarter: 2025/Q3. Revenue: 70.655M, down -10.34% YoY (top-line contraction). Profitability: Net income -11.031M (down -39.69% YoY) and EPS -0.09 (down -40.00% YoY), indicating losses deepened. Margins: Gross margin improved to 64.59% (+25.22% YoY), which is encouraging, but it has not yet translated into bottom-line improvement. Overall: Mixed quality—strong margin improvement, but deteriorating revenue and earnings trends dominate near-term fundamentals.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent change: TD Cowen (2026-01-21) raised price target to $1.65 from $1.50 and maintained Hold. Wall Street pros view (pros): Slightly improved outlook implied by the PT bump; broader beauty trends described as solid, which could support revenue upside. Wall Street cons view (cons): Hold rating signals limited confidence in near-term upside/visibility; PT is only modestly above the current price (~10%), suggesting capped return expectations.

5 Analyst Rating

Wall Street analysts forecast SKIN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SKIN is 2.13 USD with a low forecast of 1.5 USD and a high forecast of 3.5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

4 Hold

0 Sell

Hold

Current: 1.510

Low

1.5

Averages

2.13

High

3.5

Current: 1.510

Low

1.5

Averages

2.13

High

3.5

TD Cowen

Oliver Chen

Hold

maintain

AI Analysis

2026-01-21

Reason

TD Cowen

Oliver Chen

Price Target

AI Analysis

2026-01-21

maintain

Hold

Reason

TD Cowen analyst Oliver Chen raised the firm's price target on Beauty Health to $1.65 from $1.50 and keeps a Hold rating on the shares. The firm adjusted targets in the beauty space as part of a Q4 preview. TD sees the most upside potential at Estee Lauder on improving China trends and sustained U.S. momentum. Beauty trends appear solid, which should drive revenue upside for all companies, the analyst tells investors in a research note.

TD Cowen

Oliver Chen

Hold

maintain

2025-09-22

Reason

TD Cowen

Oliver Chen

Price Target

2025-09-22

maintain

Hold

Reason

TD Cowen analyst Oliver Chen raised the firm's price target on Beauty Health to $2.50 from $2 and keeps a Hold rating on the shares. The firm believes the CEO's reset is working on managing device sales (30%) churn and fostering consumables innovation (70%), along with deeper provider engagement in its 35k installed base.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SKIN

Unlock Now

SKIN Should I Buy

SKIN Should I Buy

Should You Buy Beauty Health Co (SKIN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch